<div id="readability-page-1"><h3>Claim 70% Off TipRanks Premium</h3><ul><li>Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions </li><li> Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential</li></ul>An announcement from TransThera Sciences (Nanjing). Inc. ( (HK:2617) ) is now available. TransThera Sciences (Nanjing), Inc. has been selected as a constituent of multiple Hang Seng Index Series benchmarks, including several large- and mid-cap, Stock Connect, mainland China companies, and a dedicated biotech index, effective March 9, 2026. The company will simultaneously be removed from the Hang Seng Composite SmallCap Index, a move the board interprets as evidence of rising investor recognition and a shift in its market profile toward larger-cap and more widely tracked segments, potentially broadening its investor base and liquidity. The index inclusions span key factor-based and dividend-focused indices, as well as the Hang Seng Stock Connect Hong Kong and Biotech 50 gauges, reinforcing TransThera’s visibility among both generalist and specialist healthcare investors. This reclassification may enhance the company’s standing in the Hong Kong market by aligning it with larger, more investable peers and facilitating increased participation from passive and institutional funds that follow these benchmarks. More about TransThera Sciences (Nanjing). Inc. TransThera Sciences (Nanjing), Inc. is a biopharmaceutical company listed in Hong Kong that focuses on innovative drug development, with a particular emphasis on biotech-related therapeutics. The group targets both mainland China and international capital markets, positioning itself within the broader biotech segment accessible via Stock Connect indices. Average Trading Volume: 1,931,371 Technical Sentiment Signal: Strong Sell Current Market Cap: HK$27.95B For an in-depth examination of 2617 stock, go to TipRanks’ Overview page.</div>

159740

159748

02800

TransThera Sciences (Nanjing), Inc. has been added to multiple Hang Seng Index Series benchmarks, including large- and mid-cap indices, effective March 9, 2026. The company will exit the Hang Seng Composite SmallCap Index, indicating increased investor recognition and a shift towards larger-cap segments. This reclassification may enhance its visibility and attract more institutional investment. TransThera focuses on innovative drug development in the biotech sector and aims to access both mainland China and international capital markets.

Tip Ranks

Dacheng Hang Seng Technology ETF(QDII)

Fullgoal CSI Hugangshen Innovative Drugs Industry ETF

TRACKER FUND

HSTECH ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

China Southern Hang Seng ETF

E Fund Hang Seng SCHK Innovative Drug ETF

ISHARESHSI

ChinaAMC SSE STAR Biology and Medicine ETF

ChinaAMC Hang Seng Technology ETF(QDII)

ChinaAMC SSE Health Care ETF Initiating Fund

Hang Seng TECH ETF I

Huatai-PB CSOP Hang Seng Technology ETF(QDII)

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Minsheng Royal CSI Biotechnology Theme ETF

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

ChinaAMC Hang Seng ETF

Huatai-PB Hang Seng Innovative Drugs Industry ETF(QDII)

Tianhong Hang Seng TECH ETF(QDII)

China Universal CNI HK Connect Innovative Drugs Industry ETF

Hang Seng Index

Bosera Hang Seng SCHK Innovative Drug Select ETF

E Fund CSI 300 Health Care ETF

Hwabao WP CSI Pharmaceuticals ETF

CSOP HSI ETF

Guotai CSI Bio-medicine ETF

Yinhua CSI Innovative Drugs Industry ETF

China Southern Hang Seng ETF Feeder Fund-A

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

TransThera Sciences Added to Major Hang Seng Indexes, Exits Small-Cap Gauge